YMDD Mutant Rate in Lamivudine Treatment for Hepatitis B
Author Information
Author(s): Ghandehari Freshte Pourazar, Abasali Zadeh, Mehrnaz Shanehsaz, Tajedin Nahid
Primary Institution: Islamic Azad University Fellavarjan Branch, Isfahan, Iran
Hypothesis
The study aims to determine the rate of YMDD motif mutants in lamivudine-treated chronic hepatitis B patients in Iran.
Conclusion
The study found that approximately 14% of patients developed YMDD mutations during lamivudine therapy.
Supporting Evidence
- 82% of the patients were male and 18% were female.
- 76% of patients tested positive for HBeAg.
- 61% of patients tested positive for HBsAg.
- 14% of patients developed YMDD mutations during therapy.
Takeaway
This study looked at patients taking a medicine for hepatitis B and found that some of them developed a mutation that makes the medicine less effective.
Methodology
The study tested serum samples from 33 patients using PCR and RFLP to detect YMDD mutations and measured liver enzyme levels.
Potential Biases
Potential bias may arise from the small sample size and the specific population studied.
Limitations
The study only included patients treated with lamivudine and did not account for other antiviral therapies.
Participant Demographics
82% male and 18% female, aged between 16 and 62 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website